MetaCap

Aytu BioPharma (AYTU) vs BriaCell Therapeutics (BCTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Aytu BioPharma (AYTU) has outperformed BriaCell Therapeutics (BCTX) over the past year, gaining 32.3% versus a loss of 61.7%. Over five years, AYTU leads with a -93.2% price change compared with -97.0% for BCTX. Aytu BioPharma is the larger company by market cap ($28.9 million vs $26.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AYTU+32.34%BCTX-61.75%
+64%-4%-72%
Nov 21, 20251 yearNov 20, 2026
AYTU-93.42%BCTX-97.12%
+18%-43%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AYTU versus BCTX key metrics
MetricAYTUBCTX
Share price$2.66$3.06
Market cap$28.91M$26.72M
1-day change0.00%-3.32%
YTD return+2.31%-56.96%
1-year return+32.34%-61.75%
5-year return-93.21%-97.00%
Forward P/E17.16—
EPS (TTM)$-1.78$-6.97
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$57.57M—
Revenue growth (YoY)-13.27%—
Net income (latest FY)$-14.25M$-34.90M
Gross margin63.95%—
Operating margin-14.44%—
Net margin-24.76%—
52-week high$3.07$13.09
52-week low$1.75$2.60
Distance from 52-week high-13.36%-76.62%
Analyst consensusstrong_buy—
Avg. price target upside+263.53%—
Average volume141.18K250.81K
Shares outstanding10.87M8.73M
Employees75—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AYTU has outperformed BCTX by 94.1 percentage points over the past year.

About Aytu BioPharma

AYTU stock →

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age.

Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees

About BriaCell Therapeutics

BCTX stock →

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials.

Health Care · Biotechnology: Pharmaceutical Preparations

AYTU vs BCTX FAQ

Which is bigger, Aytu BioPharma or BriaCell Therapeutics?

Aytu BioPharma (AYTU) is larger, with a market capitalization of $28.91M compared with $26.72M for BriaCell Therapeutics (BCTX).

Which stock has performed better over the past year, AYTU or BCTX?

AYTU returned +32.34% over the past 12 months, compared with -61.75% for BCTX (price return, excluding dividends). Past performance does not predict future results.

Are Aytu BioPharma and BriaCell Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons